WEKO3
アイテム
{"_buckets": {"deposit": "3514ca31-15b6-4839-b599-6a0ddf51ab59"}, "_deposit": {"created_by": 1, "id": "4310", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "4310"}, "status": "published"}, "_oai": {"id": "oai:asahikawa-med.repo.nii.ac.jp:00004310", "sets": ["7", "24"]}, "author_link": ["13433", "13424", "13432", "13430", "13428", "13425", "13429", "13420", "13421", "13422", "13426", "13423", "13427", "13431"], "item_5_biblio_info_21": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-07-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "19", "bibliographicPageStart": "15", "bibliographicVolumeNumber": "521", "bibliographic_titles": [{"bibliographic_title": "Neuroscience letters"}]}]}, "item_5_description_33": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "A series of oxicam non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be neuroprotective against 1-methyl-4-phenyl pyridinium in human neuroblastoma SH-SY5Y cells via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway independent of cyclooxygenase (COX) inhibition. The present study endeavored to establish this novel effect of meloxicam (MLX), an oxicam NSAID, in a mouse Parkinson\u0027s disease (PD) model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Male C57BL/6 mice, which received MPTP (30 mg/kg/day; s.c.) for 5 consecutive days (chronic model) with 10-day follow-up saline administrations, showed significant motor dysfunction in the pole test due to reduced tyrosine hydroxylase (TH) protein levels in the brain on day 16 after MPTP/saline treatment. Daily coadministrations of MLX (10mg/kg/day; i.p.) and MPTP for the first 5 days and follow-up 10 days with MLX administrations alone (MPTP/MLX treatment) significantly ameliorated MPTP-induced behavioral abnormalities in mice. Concomitant decreases of TH protein levels in the striatum and midbrain of MPTP/MLX-treated mice were not only significantly (p\u003c0.01 and p\u003c0.05, respectively) ameliorated but phosphorylated Akt (pAkt473) expression in the midbrain was also significantly (p\u003c0.01) increased in the midbrain when compared with MPTP/saline-treated mice. These results suggest that MLX, an oxicam NSAID, attenuated dopaminergic neuronal death in the experimental MPTP-PD model by maintenance of the Akt-signaling. Oxicam NSAIDs may serve as potential drugs for PD treatment via a novel mechanism of action.", "subitem_description_type": "Abstract"}]}, "item_5_description_36": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "Author", "subitem_description_type": "Other"}]}, "item_5_description_37": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "text", "subitem_description_type": "Other"}]}, "item_5_description_41": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "application/pdf", "subitem_description_type": "Other"}]}, "item_5_relation_24": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.neulet.2012.05.045", "subitem_relation_type_select": "DOI"}}]}, "item_5_source_id_22": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0304-3940", "subitem_source_identifier_type": "ISSN"}]}, "item_5_text_44": {"attribute_name": "ID(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "22617635"}]}, "item_5_text_51": {"attribute_name": "最終更新日(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "Sep 19, 2018 15:57:42"}]}, "item_5_text_52": {"attribute_name": "更新履歴(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "Sep 19, 2018 フリーキーワード, 月, 著者版フラグ, 著者, キーワード, DOI を変更"}]}, "item_5_text_53": {"attribute_name": "登録者(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "Library"}]}, "item_5_text_54": {"attribute_name": "閲覧数(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "808"}]}, "item_5_text_55": {"attribute_name": "ダウンロード数(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "877"}]}, "item_5_text_56": {"attribute_name": "XooNIps_ITEM_KEY", "attribute_value_mlt": [{"subitem_text_value": "5065"}]}, "item_5_text_7": {"attribute_name": "著者 ローマ字", "attribute_value_mlt": [{"subitem_text_value": "Tasaki, Yoshikazu"}]}, "item_5_version_type_38": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "田崎, 嘉一"}, {"creatorName": "タサキ, ヨシカズ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "13420", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamoto, Joe"}], "nameIdentifiers": [{"nameIdentifier": "13421", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Omura, Tomohiro"}], "nameIdentifiers": [{"nameIdentifier": "13422", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakaguchi, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "13423", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kimura, Norihisa"}], "nameIdentifiers": [{"nameIdentifier": "13424", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohtaki, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "13425", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ono, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "13426", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suno, Manabu"}], "nameIdentifiers": [{"nameIdentifier": "13427", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Asari, Masaru"}], "nameIdentifiers": [{"nameIdentifier": "13428", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohkubo, Tomoko"}], "nameIdentifiers": [{"nameIdentifier": "13429", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Noda, Toshihiro"}], "nameIdentifiers": [{"nameIdentifier": "13430", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Awaya, Toshio"}], "nameIdentifiers": [{"nameIdentifier": "13431", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Keiko"}], "nameIdentifiers": [{"nameIdentifier": "13432", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsubara, Kazuo"}], "nameIdentifiers": [{"nameIdentifier": "13433", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-07-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "5065.pdf", "filesize": [{"value": "182.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 182500.0, "url": {"label": "5065.pdf", "url": "https://asahikawa-med.repo.nii.ac.jp/record/4310/files/5065.pdf"}, "version_id": "cd397312-75f0-47b6-bbc0-ecd3a6a5b358"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Oxicam", "subitem_subject_scheme": "Other"}, {"subitem_subject": "non-steroidal anti-inflammatory drugs (NSAIDs)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Neuroprotection", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Parkinson’s disease (PD)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Akt", "subitem_subject_scheme": "Other"}, {"subitem_subject": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson\u0027s disease model", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson\u0027s disease model"}]}, "item_type_id": "5", "owner": "1", "path": ["6", "7", "24"], "permalink_uri": "https://asahikawa-med.repo.nii.ac.jp/records/4310", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-02-26"}, "publish_date": "2013-02-26", "publish_status": "0", "recid": "4310", "relation": {}, "relation_version_is_last": true, "title": ["Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson\u0027s disease model"], "weko_shared_id": -1}
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model
https://asahikawa-med.repo.nii.ac.jp/records/4310
https://asahikawa-med.repo.nii.ac.jp/records/4310a8d394a9-66ae-41d1-b1b7-4e3907991b95
名前 / ファイル | ライセンス | アクション |
---|---|---|
5065.pdf (182.5 kB)
|
|
Item type | 学術雑誌論文 / Journal Article_02(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-02-26 | |||||
タイトル | ||||||
タイトル | Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
キーワード | Oxicam | |||||
キーワード | ||||||
主題Scheme | Other | |||||
キーワード | non-steroidal anti-inflammatory drugs (NSAIDs) | |||||
キーワード | ||||||
主題Scheme | Other | |||||
キーワード | Neuroprotection | |||||
キーワード | ||||||
主題Scheme | Other | |||||
キーワード | Parkinson’s disease (PD) | |||||
キーワード | ||||||
主題Scheme | Other | |||||
キーワード | Akt | |||||
キーワード | ||||||
主題Scheme | Other | |||||
キーワード | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) | |||||
資源タイプ | ||||||
資源タイプ | journal article | |||||
著者 |
田崎, 嘉一
× 田崎, 嘉一× Yamamoto, Joe× Omura, Tomohiro× Sakaguchi, Tomoki× Kimura, Norihisa× Ohtaki, Koichi× Ono, Takashi× Suno, Manabu× Asari, Masaru× Ohkubo, Tomoko× Noda, Toshihiro× Awaya, Toshio× Shimizu, Keiko× Matsubara, Kazuo |
|||||
著者 ローマ字 | ||||||
Tasaki, Yoshikazu | ||||||
書誌情報 |
Neuroscience letters 巻 521, 号 1, p. 15-19, 発行日 2012-07-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0304-3940 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.neulet.2012.05.045 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | A series of oxicam non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be neuroprotective against 1-methyl-4-phenyl pyridinium in human neuroblastoma SH-SY5Y cells via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway independent of cyclooxygenase (COX) inhibition. The present study endeavored to establish this novel effect of meloxicam (MLX), an oxicam NSAID, in a mouse Parkinson's disease (PD) model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Male C57BL/6 mice, which received MPTP (30 mg/kg/day; s.c.) for 5 consecutive days (chronic model) with 10-day follow-up saline administrations, showed significant motor dysfunction in the pole test due to reduced tyrosine hydroxylase (TH) protein levels in the brain on day 16 after MPTP/saline treatment. Daily coadministrations of MLX (10mg/kg/day; i.p.) and MPTP for the first 5 days and follow-up 10 days with MLX administrations alone (MPTP/MLX treatment) significantly ameliorated MPTP-induced behavioral abnormalities in mice. Concomitant decreases of TH protein levels in the striatum and midbrain of MPTP/MLX-treated mice were not only significantly (p<0.01 and p<0.05, respectively) ameliorated but phosphorylated Akt (pAkt473) expression in the midbrain was also significantly (p<0.01) increased in the midbrain when compared with MPTP/saline-treated mice. These results suggest that MLX, an oxicam NSAID, attenuated dopaminergic neuronal death in the experimental MPTP-PD model by maintenance of the Akt-signaling. Oxicam NSAIDs may serve as potential drugs for PD treatment via a novel mechanism of action. | |||||
注記 | ||||||
内容記述タイプ | Other | |||||
注記 | Author | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
資源タイプ | text | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf | |||||
ID(XooNIps) | ||||||
22617635 | ||||||
閲覧数(XooNIps) | ||||||
808 | ||||||
ダウンロード数(XooNIps) | ||||||
877 |